Background: With respect to low prevalence of immunocompromised infectious diseases and their related difficulties in diagnosis and treatment, in the present study we review our experience with 3 adult and 3 infant patients with rhinocerebral mucormycosis. Materials and methods: Initial data including demographic features, clinical, laboratory and radiologic manifestations, therapeutic approach and clinical course of 6 cases of rhinocerebral mucormycosis were reviewed. Three patients died and 3 improved. Conclusion: Diabetes mellitus and metabolic cirrhosis were the most common predisposing factors. Rhinocerebral manifestations were present in all patients. Biopsy was the gold standard for diagnosis and the most efficient therapeutic approach is appropriate usage of immunosuppressive agents.

52-year-old male with type I diabetes since 16 years and chronic kidney disease since 10 years presented with pain and swelling of his right eye since 5 days associated with loss of vision since 3 days. On examination there was a blackish eschar in the right nasal cavity. Ophthalmologic examination revealed chemosis, proptosis and complete ophthalmoplegia of the right eye along with complete loss of vision (Figure 1A).....

Background: The COVID-19 was first reported in 2019 in Wuhan, China, and spread rapidly in China and other countries. The virus was followed by a wide range of bacterial and opportunistic fungal diseases, including fungal infections such as mucormycosis. Materials and methods: In this narrative review study, scientific databases, such as PubMed, Google Scholar and Springer were searched with the keywords, including Mucormycosis and COVID-19 in the time period between 2020 February and July 2021. 27 articles were retrieved, in which 18 articles were used in the study and 9 were excluded. Results: So far, many people with the coronavirus have been infected by black fungus in the world. Most affected people had the history of diabetes mellitus and also receiving high dose corticosteroids. Conclusion: Recently, with the outbreak of a new wave of the deadly Covid 19 virus in India, there have been many cases of mucormycosis. Mucocycosis is fatal in about 30% of cases.

Background: Mucormycosis is a rare disease with high mortality rate, especially in immunocompromised patients such as patients with diabetes. This study aimed to evaluate the prevalence of mucormycosis and its association with mortality rate in patients admitted to Alzahra hospital, Isfahan, Iran.Methods: 55 patients with symptomatic and definitive diagnosis of mucormycosis were enrolled in this retrospective cross-sectional study. Mortality risk factors were evaluated and compared between the dead and survived patients.Findings: Mortality rate was 29.09 percent among the patients and there was a significant relationship between the involved location and the mortality rate (P=0.02). In addition, the mortality rate was 100% in patients with disseminated infections.Conclusion: The mortality rate in patients with mucormycosis admitted to Alzahra hospital was lower than the rates reported by other studies.

Introduction: For the purpose of prognostication of sinonasal mucormycosis, a detailed analysis of the clinical, diagnostic, therapeutic and outcome parameters has been contemplated. Materials and Methods: Retrospectively data was collected for all patients of sinonasal mucormycosis managed in a tertiary care hospital in last 5years. Results: Diabetes was the commonest comorbidity among total of 52 cases. Disease extent-wise, 16, 23 and 13 patients had sino-nasal (SN), rhino-orbital (RO) and rhino-orbito-cerebral (ROC) mucormycosis respectively. Median cumulative Amphotericin-B administered was 3. 5gms and 94. 2% of cases underwent surgical debridement depending on the disease extent. With a median follow-up of 18months, 67% of the patients are alive and disease free, 2% are under treatment and 29% of patients have expired. The mortality rate was 12. 5% in SN, 30. 5% in RO and 38. 5% in ROC mucormycosis. Palatal and orbital involvement is associated with statistically significant mortality risk at one month. Conclusions: Mortality rate in sino-nasal mucormycosis can be significantly curtailed with prompt control of underlying comorbidity, aggressive medical and adequate surgical management.